Selvarangan Ponnazhagan - Publications

Affiliations: 
Pathology University of Alabama, Birmingham, Birmingham, AL, United States 
Area:
Virology Biology, Biomedical Engineering

129 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Wang H, Khattar V, Hensel JA, Ashton R, Lu Y, Sorace AG, Wang Y, Deshane JS, Mieher JL, Deivanayagam C, Ponnazhagan S. Systemic checkpoint blockade by PD-L1 single-chain antibody confers potent anti-tumor immunity and long-term survival. Molecular Cancer Therapeutics. PMID 36031328 DOI: 10.1158/1535-7163.MCT-22-0010  0.727
2020 Wang H, Ashton R, Hensel JA, Lee JH, Khattar V, Wang Y, Deshane JS, Ponnazhagan S. RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity. Molecular Cancer Therapeutics. PMID 33199500 DOI: 10.1158/1535-7163.MCT-20-0378  0.783
2020 Wang Y, Goliwas KF, Severino PE, Hough KP, Van Vessem D, Wang H, Tousif S, Koomullil RP, Frost AR, Ponnazhagan S, Berry JL, Deshane JS. Mechanical strain induces phenotypic changes in breast cancer cells and promotes immunosuppression in the tumor microenvironment. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 32572176 DOI: 10.1038/S41374-020-0452-1  0.443
2020 Kwon HJ, Qing K, Ponnazhagan S, Wang XS, Markusic DM, Gupte S, Boye S, Srivastava A. AAV D-sequence-mediated suppression of expression of a human major histocompatibility class II gene: Implications in the development of AAV vectors for modulating humoral immune response. Human Gene Therapy. PMID 32220217 DOI: 10.1089/Hum.2020.018  0.309
2020 Cha HR, Lee JH, Ponnazhagan S. Revisiting Immunotherapy: A Focus on Prostate Cancer. Cancer Research. PMID 32066566 DOI: 10.1158/0008-5472.Can-19-2948  0.455
2020 Xu X, Zhang C, Trotter TN, Gowda PS, Lu Y, Ponnazhagan S, Javed A, Li J, Yang Y. Runx2 deficiency in osteoblasts promotes myeloma progression by altering the bone microenvironment at new bone sites. Cancer Research. PMID 31911552 DOI: 10.1158/0008-5472.Can-19-0284  0.428
2019 Hensel JA, Khattar V, Ashton R, Ponnazhagan S. Recombinant AAV-CEA Tumor Vaccine in Combination with an Immune Adjuvant Breaks Tolerance and Provides Protective Immunity. Molecular Therapy Oncolytics. 12: 41-48. PMID 30666318 DOI: 10.1016/J.Omto.2018.12.004  0.77
2018 Hensel JA, Khattar V, Ashton R, Ponnazhagan S. Characterization of immune cell subtypes in three commonly used mouse strains reveals gender and strain-specific variations. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 30353130 DOI: 10.1038/S41374-018-0137-1  0.738
2018 Urbanska AM, Ponnazhagan S, Mozafari M. Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus. Cancer Research. PMID 29959150 DOI: 10.1158/0008-5472.Can-18-0206  0.346
2018 Wang Y, Schafer CC, Hough KP, Tousif S, Duncan SR, Kearney JF, Ponnazhagan S, Hsu HC, Deshane JS. Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5. Journal of Immunology (Baltimore, Md. : 1950). PMID 29752311 DOI: 10.4049/Jimmunol.1701069  0.409
2018 Kumar S, Stoke J, Malik S, Singh UP, Ponnazhagan S, Manne U, Mishra MK. Abstract 4690: FoxP3+T cells program/re-program the prostatic tumor microenvironment Immunology. 78: 4690-4690. DOI: 10.1158/1538-7445.Am2018-4690  0.428
2017 Higgs JT, Lee JH, Wang H, Ramani VC, Chanda D, Hardy CY, Sanderson RD, Ponnazhagan S. Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma. Blood Advances. 1: 2375-2385. PMID 29296887 DOI: 10.1182/Bloodadvances.2017007310  0.794
2017 Chanda D, Hensel JA, Higgs JT, Grover R, Kaza N, Ponnazhagan S. Effects of Cellular Methylation on Transgene Expression and Site-Specific Integration of Adeno-Associated Virus. Genes. 8. PMID 28926997 DOI: 10.3390/Genes8090232  0.734
2017 Moore-Smith LD, Isayeva T, Lee JH, Frost A, Ponnazhagan S. Silencing of TGF-β1 in tumor cells impacts MMP-9 in tumor microenvironment. Scientific Reports. 7: 8678. PMID 28819116 DOI: 10.1038/S41598-017-09062-Y  0.375
2017 McConnell M, Feng S, Chen W, Zhu G, Shen D, Ponnazhagan S, Deng L, Li YP. Osteoclast proton pump regulator Atp6v1c1 enhances breast cancer growth by activating the mTORC1 pathway and bone metastasis by increasing V-ATPase activity. Oncotarget. PMID 28504970 DOI: 10.18632/Oncotarget.17544  0.469
2017 Hensel JA, Khattar V, Ashton R, Lee C, Siegal GP, Ponnazhagan S. Location of tumor affects local and distant immune cell type and number. Immunity, Inflammation and Disease. 5: 85-94. PMID 28250928 DOI: 10.1002/Iid3.144  0.767
2017 Kumar S, Eroglu E, Stokes JA, Scissum-Gunn K, Saldanha SN, Singh UP, Manne U, Ponnazhagan S, Mishra MK. Resveratrol induces mitochondria-mediated, caspase-independent apoptosis in murine prostate cancer cells. Oncotarget. PMID 28157696 DOI: 10.18632/Oncotarget.14947  0.437
2017 Lee JH, Kang M, Wang H, Naik G, Mobley JA, Sonpavde G, Garvey WT, Darley-Usmar VM, Ponnazhagan S. Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 28069826 DOI: 10.1096/Fj.201601178R  0.4
2017 Kumar S, Stokes J, Singh U, Gunn KS, Manne U, Ponnazhagan S, Mishra MK. Abstract 2955: Gr1-MDSCs and Tregs modulate the prostate cancer progression Cancer Research. 77: 2955-2955. DOI: 10.1158/1538-7445.Am2017-2955  0.362
2017 Lee JH, Kang M, Naik G, Mobley JA, Sonpavde G, Garvey WT, Darley-Usmar VM, Ponnazhagan S. Abstract 1585: Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress Endocrinology. 77: 1585-1585. DOI: 10.1158/1538-7445.Am2017-1585  0.353
2016 Schafer CC, Wang Y, Hough KP, Sawant A, Grant SC, Thannickal VJ, Zmijewski J, Ponnazhagan S, Deshane JS. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment. Oncotarget. PMID 27705910 DOI: 10.18632/Oncotarget.12249  0.446
2016 Levy S, Feduska JM, Sawant A, Gilbert S, Hensel JA, Ponnazhagan S. Immature myeloid cells are critical for enhancing bone fracture healing through angiogenic cascade. Bone. PMID 27664567 DOI: 10.1016/J.Bone.2016.09.018  0.734
2016 Cha HR, Lee JH, Hensel JA, Sawant AB, Davis BH, Lee CM, Deshane JS, Ponnazhagan S. Prostate cancer-derived cathelicidin-related antimicrobial peptide facilitates macrophage differentiation and polarization of immature myeloid progenitors to protumorigenic macrophages. The Prostate. PMID 26856684 DOI: 10.1002/Pros.23155  0.778
2016 Kumar S, Stokes J, Gunn KS, Ponnazhagan S, Manne U, Mishra MK. Abstract 4328: Resveratrol inhibits NO-mediated oxidative stress in murine prostate cancer cells Cancer Research. 76: 4328-4328. DOI: 10.1158/1538-7445.Am2016-4328  0.423
2016 Feduska J, Lee C, Ponnazhagan S. Abstract 2539: Cell cycle regulation influences the phenotype of breast and prostate cancer stem cellsin vitro Cancer Research. 76: 2539-2539. DOI: 10.1158/1538-7445.Am2016-2539  0.486
2016 Kumar S, Stokes J, Gunn KS, Singh U, Ponnazhagan S, Mishra MK. Abstract 1457: Regulatory T cells and its impact on prostate cancer development and clearance Immunology. 76: 1457-1457. DOI: 10.1158/1538-7445.Am2016-1457  0.382
2016 Lee JH, Kang M, Mobley JA, Sonpavde G, Garvey WT, Darley-Usmar VM, Ponnazhagan S. Abstract 1011: Endostatin regulates androgen receptor-mediated metabolic and oxido-reductive pathways in prostate cancer cells Cancer Research. 76: 1011-1011. DOI: 10.1158/1538-7445.Am2016-1011  0.422
2015 Yu H, Liu Y, McFarland BC, Deshane JS, Hurst DR, Ponnazhagan S, Benveniste EN, Qin H. SOCS3 Deficiency in Myeloid Cells Promotes Tumor Development: Involvement of STAT3 Activation and Myeloid-Derived Suppressor Cells. Cancer Immunology Research. 3: 727-40. PMID 25649351 DOI: 10.1158/2326-6066.Cir-15-0004  0.429
2015 Higgs JT, Jarboe JS, Lee JH, Chanda D, Lee CM, Deivanayagam C, Ponnazhagan S. Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies. Molecular Cancer Research : McR. 13: 819-27. PMID 25636966 DOI: 10.1158/1541-7786.Mcr-14-0492  0.787
2015 Lee JH, Isayeva T, Larson MR, Sawant A, Cha HR, Chanda D, Chesnokov IN, Ponnazhagan S. Endostatin: A novel inhibitor of androgen receptor function in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 112: 1392-7. PMID 25605930 DOI: 10.1073/Pnas.1417660112  0.382
2015 Lee JH, Mobley JA, Ponnazhagan S. Abstract 5050: Proteome-based combined treatment strategies synergizing antagonism of androgen receptor function in prostate cancer Cancer Research. 75: 5050-5050. DOI: 10.1158/1538-7445.Am2015-5050  0.449
2015 Cha H, Hensel J, Ponnazhagan S. Abstract 434: Prostate cancer cell-derived cathelicidin-related antimicrobial peptide regulates MCP-1 and CXCL1/2 through autocrine signaling Cancer Research. 75: 434-434. DOI: 10.1158/1538-7445.Am2015-434  0.793
2014 Sawant A, Schafer CC, Ponnazhagan S, Deshane JS. The dual targeting of immunosuppressive cells and oxidants promotes effector and memory T-cell functions against lung cancer. Oncoimmunology. 3: e27401. PMID 24711958 DOI: 10.4161/Onci.27401  0.363
2014 Chanda D, Lee JH, Sawant A, Hensel JA, Isayeva T, Reilly SD, Siegal GP, Smith C, Grizzle W, Singh R, Ponnazhagan S. Anterior gradient protein-2 is a regulator of cellular adhesion in prostate cancer. Plos One. 9: e89940. PMID 24587138 DOI: 10.1371/Journal.Pone.0089940  0.793
2014 Schafer CC, Wang Y, Sawant A, Jin TH, Ponnazhagan S, Grant SC, Deshane JS. Abstract 634: Combination chemotherapy significantly reduces indoleamine 2,3-dioxygenase activity in NSCLC patients Cancer Research. 74: 634-634. DOI: 10.1158/1538-7445.Am2014-634  0.354
2014 Lee JH, Isayeva T, Larson M, Chanda D, Chesnokov I, Ponnazhagan S. Abstract 612: Endostatin is a novel inhibitor of androgen receptor function in prostate cancer Cancer Research. 74: 612-612. DOI: 10.1158/1538-7445.Am2014-612  0.435
2014 Sawant A, Lee C, Schafer C, Deshane J, Ponnazhagan S. Abstract 2794: CD8+ natural regulatory T cells as antitumor immune effectors in carcinomas of breast and lung Cancer Research. 74: 2794-2794. DOI: 10.1158/1538-7445.Am2014-2794  0.413
2014 Cha H, Sawant A, Hensel J, Lee C, Ponnazhagan S. Abstract 162: Immunomodulatory role of CRAMP (cathelicidin-related antimicrobial peptide) in prostate cancer Cancer Research. 74: 162-162. DOI: 10.1158/1538-7445.Am2014-162  0.799
2013 Sawant A, Schafer CC, Jin TH, Zmijewski J, Tse HM, Roth J, Sun Z, Siegal GP, Thannickal VJ, Grant SC, Ponnazhagan S, Deshane JS. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways. Cancer Research. 73: 6609-20. PMID 24085788 DOI: 10.1158/0008-5472.Can-13-0987  0.419
2013 Sawant A, Ponnazhagan S. Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis. Cancer Research. 73: 4606-10. PMID 23887974 DOI: 10.1158/0008-5472.Can-13-0305  0.5
2013 Sawant A, Ponnazhagan S. Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease. Oncoimmunology. 2: e24064. PMID 23762794 DOI: 10.4161/Onci.24064  0.388
2013 Sawant A, Ponnazhagan S. Role of plasmacytoid dendritic cells in breast cancer bone dissemination. Oncoimmunology. 2: e22983. PMID 23526329 DOI: 10.4161/Onci.22983  0.422
2013 Sawant A, Deshane J, Jules J, Lee CM, Harris BA, Feng X, Ponnazhagan S. Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Research. 73: 672-82. PMID 23243021 DOI: 10.1158/0008-5472.Can-12-2202  0.465
2013 Culpepper BK, Bonvallet PP, Reddy MS, Ponnazhagan S, Bellis SL. Polyglutamate directed coupling of bioactive peptides for the delivery of osteoinductive signals on allograft bone. Biomaterials. 34: 1506-13. PMID 23182349 DOI: 10.1016/J.Biomaterials.2012.10.046  0.315
2013 Cha H, Sawant A, Lee C, Hensel J, Tsuladze G, Ponnazhagan S. Abstract B86: Immunomodulatory effects of LL-37/CRAMP in prostate cancer progression. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-B86  0.494
2013 Lee CM, Sawant A, Cha H, Ponnazhagan S. Abstract 250: Growth characteristics of breast cancer stem cellsin vitroandin vivo. Cancer Research. 73: 250-250. DOI: 10.1158/1538-7445.Am2013-250  0.462
2012 Sawant A, Hensel JA, Chanda D, Harris BA, Siegal GP, Maheshwari A, Ponnazhagan S. Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells. Journal of Immunology (Baltimore, Md. : 1950). 189: 4258-65. PMID 23018462 DOI: 10.4049/Jimmunol.1101855  0.789
2012 Sawant A, Chanda D, Isayeva T, Tsuladze G, Garvey WT, Ponnazhagan S. Noggin is novel inducer of mesenchymal stem cell adipogenesis: implications for bone health and obesity. The Journal of Biological Chemistry. 287: 12241-9. PMID 22351751 DOI: 10.1074/Jbc.M111.293613  0.334
2012 Kumar S, Ponnazhagan S. Mobilization of bone marrow mesenchymal stem cells in vivo augments bone healing in a mouse model of segmental bone defect Bone. 50: 1012-1018. PMID 22342795 DOI: 10.1016/J.Bone.2012.01.027  0.391
2012 Triozzi PL, Aldrich W, Achberger S, Ponnazhagan S, Alcazar O, Saunthararajah Y. Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice. Cancer Immunology, Immunotherapy : Cii. 61: 1441-50. PMID 22310929 DOI: 10.1007/S00262-012-1204-X  0.353
2012 Chanda D, Sawant A, Hensel JA, Isayeva T, Reilly SD, Siegal GP, Smith C, Ponnazhagan S. Abstract B52: Loss of anterior gradient protein in high-grade prostate cancer is associated with loss of tumor cell adhesion and epithelial cell polarity Cancer Research. 72: B52-B52. DOI: 10.1158/1538-7445.Prca2012-B52  0.785
2012 Chanda D, Sawant A, Hensel JA, Reilly SD, Siegal GP, Smith C, Isayeva T, Ponnazhagan S. Abstract 5173: The human homologue of frog (Xenopus laevis) anterior gradient protein promotes metastasis via regulation of cellular adhesion Cancer Research. 72: 5173-5173. DOI: 10.1158/1538-7445.Am2012-5173  0.793
2012 Kumar S, Ponnazhagan S. Bone healing by endogenous stem cell mobilization Bone. 51: 635. DOI: 10.1016/J.Bone.2012.06.011  0.35
2011 Yang SW, Chanda D, Cody JJ, Rivera AA, Waehler R, Siegal GP, Douglas JT, Ponnazhagan S. Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer. Plos One. 6: e25131. PMID 22022379 DOI: 10.1371/Journal.Pone.0025131  0.409
2011 Triozzi PL, Aldrich W, Ponnazhagan S. Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists. Cancer Gene Therapy. 18: 850-8. PMID 21869824 DOI: 10.1038/Cgt.2011.54  0.403
2011 Yang SW, Cody JJ, Rivera AA, Waehler R, Wang M, Kimball KJ, Alvarez RA, Siegal GP, Douglas JT, Ponnazhagan S. Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 538-49. PMID 21115652 DOI: 10.1158/1078-0432.Ccr-10-1628  0.382
2011 Hensel JA, Chanda D, Kumar S, Sawant A, Grizzle WE, Siegal GP, Ponnazhagan S. LL-37 as a therapeutic target for late stage prostate cancer. The Prostate. 71: 659-70. PMID 20957672 DOI: 10.1002/Pros.21282  0.763
2011 Chanda D, Sawant A, Isayeva T, Ponnazhagan S. Abstract 5261: Role of anterior gradient protein-2 in prostate cancer bone metastasis Cancer Research. 71: 5261-5261. DOI: 10.1158/1538-7445.Am2011-5261  0.487
2011 Higgs JT, Jarboe J, Ponnazhagan S. Abstract 3391: Regenerative stem cell therapy for multiple myeloma osteolytic bone damage Cancer Research. 71: 3391-3391. DOI: 10.1158/1538-7445.Am2011-3391  0.788
2010 Triozzi PL, Aldrich W, Ponnazhagan S. Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists. Vaccine. 28: 7837-43. PMID 20937315 DOI: 10.1016/J.Vaccine.2010.09.086  0.381
2010 Lee JH, Moore LD, Kumar S, Pritchard DG, Ponnazhagan S, Deivanayagam C. Bacteriophage hyaluronidase effectively inhibits growth, migration and invasion by disrupting hyaluronan-mediated Erk1/2 activation and RhoA expression in human breast carcinoma cells. Cancer Letters. 298: 238-49. PMID 20688428 DOI: 10.1016/J.Canlet.2010.07.011  0.748
2010 Andea AA, Patel R, Ponnazhagan S, Kumar S, DeVilliers P, Jhala D, Eltoum IE, Siegal GP. Merkel cell carcinoma: correlation of KIT expression with survival and evaluation of KIT gene mutational status. Human Pathology. 41: 1405-12. PMID 20594584 DOI: 10.1016/J.Humpath.2010.02.010  0.369
2010 Chanda D, Kumar S, Ponnazhagan S. Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton Journal of Cellular Biochemistry. 111: 249-257. PMID 20506559 DOI: 10.1002/Jcb.22701  0.38
2010 Kumar S, Wan C, Ramaswamy G, Clemens TL, Ponnazhagan S. Mesenchymal stem cells expressing osteogenic and angiogenic factors synergistically enhance bone formation in a mouse model of segmental bone defect. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 1026-34. PMID 20068549 DOI: 10.1038/Mt.2009.315  0.375
2010 Kumar S, Nagy TR, Ponnazhagan S. Therapeutic potential of genetically modified adult stem cells for osteopenia Gene Therapy. 17: 105-116. PMID 19741731 DOI: 10.1038/Gt.2009.116  0.399
2010 Moore LD, Isayeva T, Gurley J, Ponnazhagan S. Abstract 541: TGF-β signaling in the tumor microenvironment promotes tumor formation and tumor progression Cancer Research. 70: 541-541. DOI: 10.1158/1538-7445.Am10-541  0.73
2010 Chanda D, Sawant A, Isayeva T, Ponnazhagan S. Abstract 231: Mechanism of bone metastasis in prostate cancer: Role of anterior gradient homolog 2 Cancer Research. 70: 231-231. DOI: 10.1158/1538-7445.Am10-231  0.511
2010 Isayeva T, Chanda D, Tsuladze G, Moore L, Ponnazhagan S. Abstract 1246: Mechanism of endostatin action in prostate cancer in dependent on androgen receptor signaling Cancer Research. 70: 1246-1246. DOI: 10.1158/1538-7445.Am10-1246  0.754
2009 Andea AA, Patel R, Ponnazhagan S, Kumar S, DeVilliers P, Jhala D, Eltoum I, Manne U, Siegal G. Detection of Merkel cell polyomavirus in formalin-fixed, paraffin-embedded tissue of Merkel cell carcinoma and its correlation with prognosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6027. PMID 27962435 DOI: 10.1200/Jco.2009.27.15_Suppl.6027  0.358
2009 Chanda D, Isayeva T, Kumar S, Hensel JA, Sawant A, Ramaswamy G, Siegal GP, Beatty MS, Ponnazhagan S. Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7175-85. PMID 19920103 DOI: 10.1158/1078-0432.Ccr-09-1938  0.778
2009 Byon CH, Hardy RW, Ren C, Ponnazhagan S, Welch DR, McDonald JM, Chen Y. Free fatty acids enhance breast cancer cell migration through plasminogen activator inhibitor-1 and SMAD4. Laboratory Investigation; a Journal of Technical Methods and Pathology. 89: 1221-8. PMID 19752858 DOI: 10.1038/Labinvest.2009.97  0.393
2009 Westbrook L, Ramanathan HN, Isayeva T, Mittal AR, Qu Z, Johnson MD, Kern FG, Ponnazhagan S, Grubbs CJ, Thottassery JV. High Cks1 expression in transgenic and carcinogen-initiated mammary tumors is not always accompanied by reduction in p27Kip1. International Journal of Oncology. 34: 1425-31. PMID 19360356 DOI: 10.3892/Ijo_00000271  0.427
2009 Isayeva T, Moore LD, Chanda D, Chen D, Ponnazhagan S. Tumoristatic effects of endostatin in prostate cancer is dependent on androgen receptor status. The Prostate. 69: 1055-66. PMID 19301304 DOI: 10.1002/Pros.20952  0.737
2008 White AF, Mazur M, Sorscher EJ, Zinn KR, Ponnazhagan S. Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells. Human Gene Therapy. 19: 1407-14. PMID 18778196 DOI: 10.1089/Hum.2008.117  0.354
2008 Shammas MA, Qazi A, Batchu RB, Bertheau RC, Wong JY, Rao MY, Prasad M, Chanda D, Ponnazhagan S, Anderson KC, Steffes CP, Munshi NC, De Vivo I, Beer DG, Gryaznov S, et al. Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4971-80. PMID 18676772 DOI: 10.1158/1078-0432.Ccr-08-0473  0.334
2008 Moore LD, Isayeva T, Siegal GP, Ponnazhagan S. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4961-70. PMID 18676771 DOI: 10.1158/1078-0432.Ccr-07-4604  0.721
2008 Ren C, Kumar S, Chanda D, Chen J, Mountz JD, Ponnazhagan S. Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells (Dayton, Ohio). 26: 2332-8. PMID 18617688 DOI: 10.1634/Stemcells.2008-0084  0.392
2008 Ren C, Kumar S, Chanda D, Kallman L, Chen J, Mountz JD, Ponnazhagan S. Cancer gene therapy using mesenchymal stem cells expressing interferon-β in a mouse prostate cancer lung metastasis model Gene Therapy. 15: 1446-1453. PMID 18596829 DOI: 10.1038/Gt.2008.101  0.475
2008 Chanda D, Isayeva T, Kumar S, Siegal GP, Szafran AA, Zinn KR, Reddy VV, Ponnazhagan S. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 871-8. PMID 18388919 DOI: 10.1038/Mt.2008.48  0.47
2008 Kumar S, Chanda D, Ponnazhagan S. Therapeutic potential of genetically modified mesenchymal stem cells. Gene Therapy. 15: 711-5. PMID 18356815 DOI: 10.1038/Gt.2008.35  0.377
2008 Shammas MA, Qazi A, Batchu RB, Bertheau RC, Wong JY, Rao MY, Bryant CS, Kumar S, Prasad M, Ponnazhagan S, Chanda D, Steffes CP, Munshi NC, De Vivo I, Beer DG, et al. W1953 Effect of a Novel Telomerase Inhibitor, Grn163l, On Growth of Barrett's Esophageal Adenocarcinoma Cells In Vitro and In Vivo Gastroenterology. 134: A-741. DOI: 10.1016/S0016-5085(08)63460-5  0.315
2007 Kumar S, Ponnazhagan S. Bone homing of mesenchymal stem cells by ectopic alpha 4 integrin expression. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 21: 3917-27. PMID 17622670 DOI: 10.1096/Fj.07-8275Com  0.411
2007 Isayeva T, Chanda D, Kallman L, Eltoum IE, Ponnazhagan S. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Research. 67: 5789-97. PMID 17575146 DOI: 10.1158/0008-5472.Can-06-3637  0.467
2007 Pereboeva L, Komarova S, Roth J, Ponnazhagan S, Curiel DT. Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus Gene Therapy. 14: 627-637. PMID 17251987 DOI: 10.1038/Sj.Gt.3302916  0.302
2007 Ren C, White AF, Ponnazhagan S. Notch1 augments intracellular trafficking of adeno-associated virus type 2. Journal of Virology. 81: 2069-73. PMID 17151095 DOI: 10.1128/Jvi.01811-06  0.419
2006 White AF, Ponnazhagan S. Airway epithelium directed gene therapy for cystic fibrosis. Medicinal Chemistry (ShāRiqah (United Arab Emirates)). 2: 499-503. PMID 17017989 DOI: 10.2174/157340606778250180  0.327
2006 Isayeva T, Ren C, Ponnazhagan S. Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway. Gene Therapy. 14: 138-46. PMID 16943851 DOI: 10.1038/Sj.Gt.3302853  0.396
2006 Sorscher EJ, Harris J, Alexander M, Rottgers A, Hardy K, Ponnazhagan S, Collawn JF, McClintock J, Amsler CD, Webster A, Maddry J, Baker BJ, Hong JS. Activators of viral gene expression in polarized epithelial monolayers identified by rapid-throughput drug screening. Gene Therapy. 13: 781-8. PMID 16307002 DOI: 10.1038/Sj.Gt.3302676  0.344
2006 Kumar S, Nagy TR, Ponnazhagan S. 568. Ex Vivo Mesenchymal Stem Cell Therapy with rAAV2 Encoding BMP-2 Enhances Bone Regeneration in Ovariectomized Mouse Model Molecular Therapy. 13: S219. DOI: 10.1016/J.Ymthe.2006.08.641  0.403
2006 Isayeva T, Chanda D, Ponnazhagan S. 295. Effects of Sustained Anti-Angiogenic Gene Therapy in Multi-Stage Prostate Cancer in TRAMP Mice Molecular Therapy. 13: S112. DOI: 10.1016/J.Ymthe.2006.08.350  0.475
2006 Ren C, White AF, Ponnazhagan S. 4. Role of Notch1 in Augmenting Intracellular Trafficking and Transgene Expression of Recombinant Adeno-Associated Virus-2 Molecular Therapy. 13: S2. DOI: 10.1016/J.Ymthe.2006.08.014  0.421
2005 Batchu RB, Moreno AM, Szmania SM, Bennett G, Spagnoli GC, Ponnazhagan S, Barlogie B, Tricot G, van Rhee F. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Research. 65: 10041-9. PMID 16267030 DOI: 10.1158/0008-5472.Can-05-1383  0.326
2005 Kumar S, Mahendra G, Ponnazhagan S. Determination of osteoprogenitor-specific promoter activity in mouse mesenchymal stem cells by recombinant adeno-associated virus transduction. Biochimica Et Biophysica Acta. 1731: 95-103. PMID 16225939 DOI: 10.1016/J.Bbaexp.2005.08.007  0.358
2005 Ren C, Kumar S, Shaw DR, Ponnazhagan S. Genomic stability of self-complementary adeno-associated virus 2 during early stages of transduction in mouse muscle in vivo. Human Gene Therapy. 16: 1047-57. PMID 16149903 DOI: 10.1089/Hum.2005.16.1047  0.315
2005 Mahendra G, Kumar S, Isayeva T, Mahasreshti PJ, Curiel DT, Stockardt CR, Grizzle WE, Alapati V, Singh R, Siegal GP, Meleth S, Ponnazhagan S. Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor. Cancer Gene Therapy. 12: 26-34. PMID 15359287 DOI: 10.1038/Sj.Cgt.7700754  0.449
2005 Aldrich WA, Ren C, White A, Zhou S, Kumar S, Jenkins CB, Shaw DR, Strong TV, Triozzi PL, Ponnazhagan S. 849. Transduction of Mouse Dendritic Cells Is Enhanced by Repetitive Infection with Self-Complementary Adeno-Associated Virus 6 Combined with Immunostimulatory Ligands Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.392  0.371
2005 White AF, Mazur M, Sorscher EJ, Ponnazhagan S. 507. Modeling Adeno-Associated Virus 2 Capsid for the Identification of Targeting Ligands for Enhanced Gene Transfer to Polarized Human Airway Epithelial Cells Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.047  0.354
2005 Kumar S, Ponnazhagan S. 136. Recombinant Adeno-Associated Virus 2-Mediated Ectopic Expression of |[alpha]|4|[beta]|1 Integrin in Mouse Mesenchymal Stem Cells Enhances Repopulation to Bone upon Syngeneic Transplantation in an Immunocompetent Mouse Model Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.141  0.424
2005 Isayeva T, Ren C, Ponnazhagan S. 119. Intraperitoneal Transduction of Adeno-Associated Virus 2 Expressing Angiostatin and Endostatin Synergistically Augments Paclitaxel Therapy and Tumor-Free Survival in a Mouse Model of Epithelial Ovarian Cancer Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.124  0.447
2004 Chaudhuri TR, Cao Z, Ponnazhagan S, Stargel A, Simhadri PL, Zhou T, Lobuglio AF, Buchsbaum DJ, Zinn KR. Detection of disseminated breast cancer growth and treatment response using non-invasive bioluminescence imaging. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 742. PMID 28013631 DOI: 10.1200/Jco.2004.22.14_Suppl.742  0.372
2004 Kumar S, Mahendra G, Nagy TR, Ponnazhagan S. Osteogenic differentiation of recombinant adeno-associated virus 2-transduced murine mesenchymal stem cells and development of an immunocompetent mouse model for ex vivo osteoporosis gene therapy. Human Gene Therapy. 15: 1197-206. PMID 15684696 DOI: 10.1089/Hum.2004.15.1197  0.418
2004 Kumar S, Ponnazhagan S. Gene therapy for osteoinduction. Current Gene Therapy. 4: 287-96. PMID 15384942 DOI: 10.2174/1566523043346219  0.383
2004 Ponnazhagan S, Mahendra G, Lima J, Aldrich WA, Jenkins CB, Ren C, Kumar S, Kallman L, Strong TV, Shaw DR, Triozzi PL. Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant. Human Gene Therapy. 15: 856-64. PMID 15353040 DOI: 10.1089/Hum.2004.15.856  0.409
2004 Isayeva T, Kumar S, Ponnazhagan S. Anti-angiogenic gene therapy for cancer (review). International Journal of Oncology. 25: 335-43. PMID 15254730  0.304
2004 Ponnazhagan S, Mahendra G, Kumar S, Shaw DR, Stockard CR, Grizzle WE, Meleth S. Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Research. 64: 1781-7. PMID 14996740 DOI: 10.1158/0008-5472.Can-03-1786  0.434
2004 Ponnazhagan S, Hoover F. Delivery of DNA to tumor cells in vivo using adeno-associated virus. Methods in Molecular Biology (Clifton, N.J.). 246: 237-43. PMID 14970597 DOI: 10.1385/1-59259-650-9:237  0.435
2004 Ponnazhagan S. Parvovirus vectors for cancer gene therapy. Expert Opinion On Biological Therapy. 4: 53-64. PMID 14680468 DOI: 10.1517/14712598.4.1.53  0.388
2004 Isayeva T, Kumar S, Ponnazhagan S. Anti-angiogenic gene therapy for cancer (review). International Journal of Oncology. 25: 335-343. DOI: 10.3892/Ijo.25.2.335  0.418
2004 Kumar S, Mahendra G, Ponnazhagan S. 886. Determination of Osteoprogenitor-Specific Promoter Activity in Murine Mesenchymal Stem Cells by Recombinant Adeno-Associated Virus Transduction Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.792  0.423
2004 Ren C, Kumar S, Ponnazhagan S. 746. Genomic Stability of Self-Complementary Recombinant Adeno-Associated Virus 2 in Mouse Muscle Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.668  0.302
2004 Ponnazhagan S, Mahendra G, Lima J, Aldrich W, Jenkins C, Ren C, Kumar S, Kallman L, Strong TV, Shaw DR, Triozzi PL. 619. Augmentation of Anti-Tumor Activity of a Recombinant Adeno-Associated Virus 2 Carcinoembryonic Antigen Vaccine with Plasmid Adjuvants Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.543  0.423
2004 Isayeva T, Ren C, Ponnazhagan S. 434. Recombinant Adeno-Associated Virus 2 -Mediated Anti-Angiogenic Gene Therapy in a Mouse Model of Intraperitoneal Ovarian Cancer Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.400  0.44
2002 Ponnazhagan S, Mahendra G, Kumar S, Thompson JA, Castillas M. Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. Journal of Virology. 76: 12900-7. PMID 12438615 DOI: 10.1128/Jvi.76.24.12900-12907.2002  0.358
2001 Ponnazhagan S, Mahendra G, Curiel DT, Shaw DR. Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: Implications for ex vivo immunotherapy Journal of Virology. 75: 9493-9501. PMID 11533211 DOI: 10.1128/Jvi.75.19.9493-9501.2001  0.353
1999 Kurpad C, Mukherjee P, Wang XUS, Ponnazhagan S, Li L, Yoder MC, Srivastava A. Adeno-associated virus 2-mediated transduction and erythroid lineage- restricted expression from parvovirus B19p6 promoter in primary human hematopoietic progenitor cells Journal of Hematotherapy and Stem Cell Research. 8: 585-592. PMID 10645765 DOI: 10.1089/152581699319740  0.387
1998 Mah C, Qing K, Khuntirat B, Ponnazhagan S, Wang XS, Kube DM, Yoder MC, Srivastava A. Adeno-associated virus type 2-mediated gene transfer: Role of epidermal growth factor receptor protein tyrosine kinase in transgene expression Journal of Virology. 72: 9835-9843. PMID 9811719 DOI: 10.1128/Jvi.72.12.9835-9843.1998  0.355
1998 Ponnazhagan S, Weigel KA, Raikwar SP, Mukherjee P, Yoder MC, Srivastava A. Recombinant human parvovirus B19 vectors: Erythroid cell-specific delivery and expression of transduced genes Journal of Virology. 72: 5224-5230. PMID 9573295 DOI: 10.1128/Jvi.72.6.5224-5230.1998  0.373
1998 Qing K, Khuntirat B, Mah C, Kube DM, Wang XS, Ponnazhagan S, Zhou S, Dwarki VJ, Yoder MC, Srivastava A. Adeno-associated virus type 2-mediated gene transfer: correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo. Journal of Virology. 72: 1593-9. PMID 9445062 DOI: 10.1128/Jvi.72.2.1593-1599.1998  0.381
1997 Ponnazhagan S, Mukherjee P, Wang XS, Qing K, Kube DM, Mah C, Kurpad C, Yoder MC, Srour EF, Srivastava A. Adeno-associated virus type 2-mediated transduction in primary human bone marrow-derived CD34+ hematopoietic progenitor cells: donor variation and correlation of transgene expression with cellular differentiation. Journal of Virology. 71: 8262-7. PMID 9343178 DOI: 10.1128/Jvi.71.11.8262-8267.1997  0.402
1997 Ponnazhagan S, Mukherjee P, Yoder MC, Wang XS, Zhou SZ, Kaplan J, Wadsworth S, Srivastava A. Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. Gene. 190: 203-10. PMID 9185868 DOI: 10.1016/S0378-1119(96)00576-8  0.357
1997 Ponnazhagan S, Yoder MC, Srivastava A. Adeno-associated virus type 2-mediated transduction of murine hematopoietic cells with long-term repopulating ability and sustained expression of a human globin gene in vivo Journal of Virology. 71: 3098-3104. PMID 9060672 DOI: 10.1128/Jvi.71.4.3098-3104.1997  0.405
1997 Ponnazhagan S, Erikson D, Kearns WG, Zhou SZ, Nahreini P, Wang XS, Srivastava A. Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells. Human Gene Therapy. 8: 275-84. PMID 9048194 DOI: 10.1089/Hum.1997.8.3-275  0.304
1997 Kube DM, Ponnazhagan S, Srivastava A. Encapsidation of adeno-associated virus type 2 Rep proteins in wild-type and recombinant progeny virions: Rep-mediated growth inhibition of primary human cells. Journal of Virology. 71: 7361-7371. DOI: 10.1128/Jvi.71.10.7361-7371.1997  0.363
1996 Srivastava A, Wang XS, Ponnazhagan S, Zhou SZ, Yoder MC. Adeno-associated virus 2-mediated transduction and erythroid lineage-specific expression in human hematopoietic progenitor cells Current Topics in Microbiology and Immunology. 218: 93-117. PMID 8794248 DOI: 10.1007/978-3-642-80207-2_7  0.313
1996 Ponnazhagan S, Wang XS, Woody MJ, Luo F, Kang LY, Nallari ML, Munshi NC, Zhou SZ, Srivastava A. Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: human megakaryocytic leukaemia cells are non-permissive for AAV infection. The Journal of General Virology. 77: 1111-22. PMID 8683195 DOI: 10.1099/0022-1317-77-6-1111  0.363
1996 Broxmeyer HE, Cooper S, Etienne-Julan M, Wang XS, Ponnazhagan S, Braun S, Lu L, Srivastava A. Cord blood transplantation and the potential for gene therapy. Gene transduction using a recombinant adeno-associated viral vector. Annals of the New York Academy of Sciences. 770: 105-15. PMID 8597353 DOI: 10.1111/J.1749-6632.1995.Tb31048.X  0.328
1995 Ponnazhagan S, Woody MJ, Wang XS, Zhou SZ, Srivastava A. Transcriptional transactivation of parvovirus B19 promoters in nonpermissive human cells by adenovirus type 2. Journal of Virology. 69: 8096-101. PMID 7494329 DOI: 10.1128/Jvi.69.12.8096-8101.1995  0.34
1994 Ponnazhagan S, Hou L, Kwon BS. Structural organization of the human tyrosinase gene and sequence analysis and characterization of its promoter region. The Journal of Investigative Dermatology. 102: 744-8. PMID 8176257 DOI: 10.1111/1523-1747.Ep12376924  0.308
1992 Ponnazhagan S, Kwon BS. A cis-acting element involved in mouse tyrosinase gene expression and partial purification of its binding protein Pigment Cell Research / Sponsored by the European Society For Pigment Cell Research and the International Pigment Cell Society. 5: 155-161. PMID 1494537 DOI: 10.1111/J.1600-0749.1992.Tb00453.X  0.358
Show low-probability matches.